JP2007517006A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517006A5
JP2007517006A5 JP2006546305A JP2006546305A JP2007517006A5 JP 2007517006 A5 JP2007517006 A5 JP 2007517006A5 JP 2006546305 A JP2006546305 A JP 2006546305A JP 2006546305 A JP2006546305 A JP 2006546305A JP 2007517006 A5 JP2007517006 A5 JP 2007517006A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
formula
amino
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006546305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517006A (ja
Filing date
Publication date
Priority claimed from GB0330001A external-priority patent/GB0330001D0/en
Priority claimed from GB0416850A external-priority patent/GB0416850D0/en
Application filed filed Critical
Priority claimed from PCT/GB2004/005332 external-priority patent/WO2005060969A1/en
Publication of JP2007517006A publication Critical patent/JP2007517006A/ja
Publication of JP2007517006A5 publication Critical patent/JP2007517006A5/ja
Pending legal-status Critical Current

Links

JP2006546305A 2003-12-24 2004-12-20 Tie2(tek)活性のあるピリミジン Pending JP2007517006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0330001A GB0330001D0 (en) 2003-12-24 2003-12-24 Compounds
GB0416850A GB0416850D0 (en) 2004-07-29 2004-07-29 Compounds
PCT/GB2004/005332 WO2005060969A1 (en) 2003-12-24 2004-12-20 Pyrimidines with tie2 (tek) activity

Publications (2)

Publication Number Publication Date
JP2007517006A JP2007517006A (ja) 2007-06-28
JP2007517006A5 true JP2007517006A5 (enExample) 2008-02-07

Family

ID=34712716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546305A Pending JP2007517006A (ja) 2003-12-24 2004-12-20 Tie2(tek)活性のあるピリミジン

Country Status (10)

Country Link
US (1) US20080027076A1 (enExample)
EP (1) EP1737462B1 (enExample)
JP (1) JP2007517006A (enExample)
AR (1) AR046996A1 (enExample)
AT (1) ATE402705T1 (enExample)
DE (1) DE602004015509D1 (enExample)
ES (1) ES2309591T3 (enExample)
TW (1) TW200524607A (enExample)
UY (1) UY28700A1 (enExample)
WO (1) WO2005060969A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410913B (de) * 2001-08-14 2003-08-25 Schelling Anlagenbau Gmbh Auflagetisch für eine trennsäge mit einem maschinentisch
ATE415970T1 (de) * 2003-12-24 2008-12-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
US20080146599A1 (en) * 2005-02-01 2008-06-19 Astrazeneca Ab Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
US20100048543A1 (en) * 2005-02-01 2010-02-25 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP2008534565A (ja) * 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Tie2阻害活性のあるアミノピリミジン誘導体
AU2013201242B2 (en) * 2005-12-23 2015-05-07 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
AU2015210454B2 (en) * 2005-12-23 2016-10-27 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
HUE047422T2 (hu) 2005-12-23 2020-04-28 Ariad Pharma Inc Biciklusos heteroaril vegyületek
EA200870514A1 (ru) 2006-05-08 2009-04-28 Ариад Фармасьютикалз, Инк. Ацетиленовые гетероарильные соединения
ES2555515T3 (es) 2006-05-08 2016-01-04 Ariad Pharmaceuticals, Inc. Compuestos de heteroarilo monocíclico
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
AU2009275957A1 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
AU2009314631B2 (en) 2008-11-12 2014-07-31 Takeda Pharmaceutical Company Limited Pyrazinopyrazines and derivatives as kinase inhibitors
UY33198A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
ES2747249T3 (es) * 2014-07-17 2020-03-10 Sunshine Lake Pharma Co Ltd Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer
US10870647B2 (en) 2016-06-20 2020-12-22 Daegu-Gyeongbuk Medical Innovation Foundation Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer
US11213529B2 (en) 2017-07-13 2022-01-04 Sunshine Lake Pharma Co., Ltd. Salt of substituted urea derivative and use thereof in medicine
US20210284647A1 (en) * 2018-07-10 2021-09-16 Voronoibio Inc. N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases
CN110272426B (zh) 2018-07-17 2022-05-31 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基(杂)芳环类化合物
EP4105217A4 (en) * 2020-02-28 2023-09-06 Daegu-Gyeongbuk Medical Innovation Foundation 3-((8-((1H-PYRAZOL-4-YL))AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION THE CONTAINER AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261327B1 (en) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2007517006A5 (enExample)
JP2007517007A5 (enExample)
JP5925394B2 (ja) 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
JP6524081B2 (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
CN103121996B (zh) 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
JP5941598B2 (ja) 5員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
JP6013375B2 (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
AU2012210489B2 (en) IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
KR101551238B1 (ko) 신규한 hiv 역전사효소 억제제
US10202390B2 (en) Heteroaryl substituted aminopyridine compounds
BRPI0720043A2 (pt) Composto oxadiazol
WO2014181287A1 (en) Heterocyclyl compounds and uses thereof
AU2007325403A1 (en) Methods of treating cognitive impairment and dementia
JP2009534406A5 (enExample)
EP2668183A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
CN102361868A (zh) 作为1-磷酸-鞘氨醇激动剂的吡唑-1,2,4-噁二唑衍生物
JP2018526405A5 (enExample)
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
JP2003529593A5 (enExample)
JP2015502371A5 (enExample)
JP7597710B2 (ja) 置換インドール二量体の化合物
KR101536488B1 (ko) 이미다졸 유도체, 그의 제조 방법 및 용도
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
JP7573596B2 (ja) Irak4阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2024138201A2 (en) Selective bet inhibitors and uses thereof